Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...